ǰÑÔ
×Ô¾õÐÔÒÅ´«Ä£×ÓΪÑо¿ñ²ðïÈ«ÉíÐÔ±¬·¢£¬ÌØÊâÊÇÑо¿ñ²ðïʧÉñ±¬·¢ÌṩÁË»ù´¡¡£WAG/Rij´óÊóÓÃÓÚÑо¿ÒÅ´«ÐÔñ²ðïʧÉñ±¬·¢£¬ÆäÐÐΪѧ¸Ä±ä¡¢EEGÌåÏÖ£¨ÌåÏÖΪ¼¬Âý¸´ºÏ°å²¨£©ÒÔ¼°ÒÅ´«ÌØÕ÷µÈ·½ÃæÓëÈËÀàñ²ðïʧÉñ±¬·¢¼«ÎªÏàÏñ£¬Òѱ»ÆÕ±éÓÃÓÚÑо¿ÈËÀàñ²ðïʧÉñ±¬·¢¡£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯Î´óÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
WAG/Rij´óÊóȪԴÓÚ1924ÄêBacharachÅàÓýµÄÔ¶½»ÏµWistar»ùÒòÍ»±ä´óÊó¡£
¡¾Ä£×ÓÌØµã¡¿£º
ÏÖÔÚ³£ÓõÄʧÉñ±¬·¢ÒÅ´«Ä£×ÓÖ÷ҪΪWAG/Rij´óÊó£¬ÎÞÂÛÊÇÔÚËÕÐÑ»ò˯Ãß״̬Ï£¬¾ùÄܼͼµ½Ë«²àͬ²½¡¢Õó·¢ÐԵגּ¨·¢·ÅºÍÁ½²àͬ²½¶Ô³ÆµÄ3Hz¼¬Âý²¨·¢·Å(spike and wave discharges,SWDs)£¬Í¬Ê±°éÓÐÁÙ´²Ê§Éñ±¬·¢µÄÌåÏÖ¡£
¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º
ÄÜÏÔÖøÒÖÖÆ¸ÃÄ£×ÓʧÉñ±¬·¢µÄÒ©ÎïÍùÍù¶ÔÁÙ´²Ê§Éñ±¬·¢ÓÐÓã¬Á½Õß¼ä¾ßÓи߶ÈÏà¹ØÐÔ¡£g£°±»ù¶¡ËáB1¼¤¶¯¼ÁÄܼÓÖØWAG/Rij´óÊóÄ£×ÓµÄSWDs·¢·Å¡£Ö»¹ÜÉÏÊöÁ½ÖÖÒÅ´«ÐÔʧÉñÄ£×Ó¾ßÓÐ×Ô¾õʧÉñ±¬·¢¼°SWDs£¬µ«ÒòÄÑÒÔ´ó×Ú×ÌÉú£¬´Ó¶øÊ¹ÆäÓ¦ÓÃÊܵ½ÏÞÖÆ¡£
²Î¿¼ÎÄÏ×£º
1.Andrè V, Dube C, Francois J, et al. Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model. Epilepsia,2007,48 (Suppl 5):41-47
2.Gareri P, Condorelli D, Bellua.rdo N, el al. Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice).Neuropharmacology, 2005, 49 (4):551-563
3.Holmes GL. Animal model studies application to human patients. Neurology, 2007, 69 (24 Suppl 3): S28-32
4.Jefferys JG. Models and mechanisms of experimental epilepsies. Epilepsia, 2003, 44 (Suppl 12):44-50
5.Löscher W,Leppik IE. Critical re-evaluation of previous preclinical strategies for the cliscovery and the development of new anliepileplic drugs. Epilepsy Res, 2002, 50 (1-2):17-20
6.Löscher W,Schmidt D.Stralegies in aatiepileptic drug development: is rational drug design superior to random screening and structural variation?Epilepsy Res, 1994, 17 (2):95-134
7.Wang Y, Zhou D, Wang B, el al. A kindling model of pharmacoresislanl temporal lobe epilepsy in SpragueDawley rats induced by Coriaria lactone and its possible mechanism. Epilepsia,2003,44(4):475-488
8.White HS. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia, 2003, 44 (Suppl 7):2-8